Shukra Pharmaceuticals (BOM:524632) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524632 Shukra Pharmaceuticals Ltd BOM:524632
67 GF Score
Price ₹51.96
GF Value ₹31.01
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Shukra Pharmaceuticals Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Shukra Pharmaceuticals Quality Rank Related Terms

BOM:524632
67GF Score
Shukra Pharmaceuticals Ltd BOM:524632
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Shukra Pharmaceuticals (BOM:524632) Overvalued in 2026?

Based on GuruFocus' analysis, Shukra Pharmaceuticals stock appears to be overvalued. The current stock price of ₹51.96 is trading 67.6% above its estimated GF Value™ of ₹31.01. GuruFocus considers Shukra Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for BOM:524632:

  • Quality Rank:
  • GF Value™: ₹31.01 vs. price of ₹51.96 (67.6% above fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the BOM:524632 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shukra Pharmaceuticals Business Description

Other Exchanges SHUKRAPHAR:India
Address Judges Bunglow Road, Bodakdev, 3rd Floor, Dev House, Opposite WIAA Office, Ahmedabad, GJ, IND, 380054
Shukra Pharmaceuticals Ltd is engaged in the business of manufacturing and trading pharmaceutical products. The company markets its products in India and international markets. The company has two operating segments: Pharmaceutical and Laboratory. Its product portfolio includes antibiotics, quinolones, macrolides, antibacterials, antifungals, antimalarials, antivirals, antiprotozoals, anthelmintics, antidepressants, antimanics, antiemetics, beta-blockers, analgesics, muscle relaxants, antituberculosis agents, vitamin products, antiallergics, corticosteroids, hyperglycemic and hypoglycemic agents, and others. It exports its products to Australia, Uganda, Kenya, the United Kingdom, Sri Lanka, Mauritius, and the Republic of Yemen.
67GF Score

Get the complete analysis for BOM:524632

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹51.96
Price
₹31.01
GF Value